http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006516530-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-28 |
| filingDate | 2003-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006516530-A |
| titleOfInvention | Functionalized metallocenes as anticancer drugs |
| abstract | The present invention provides a formula (1) for use as a medicament in treating cancer. [Chemical 1] The metallocene compound represented by these is provided. In formula (1), R 1 , R 2 , R 3 and R 4 represent a combination of H, alkyl, aryl or trimethylsilyl, L represents a side chain substituent, at least one of which is Contains a group that allows the compound to become soluble in water, X is halo, alkoxy, acetate or H 2 O, Y is a counter ion, and M is a metal. The present invention also provides a novel compound of formula (1) wherein at least one of the L groups comprises a quaternary tetraalkylammonium group. It has been found that this compound shows significantly higher activity in the treatment of cancer than compounds known in the prior art. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014516075-A |
| priorityDate | 2002-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.